Soaring Demand Set to Propel Personalized Gene Therapy Treatment Market to $17.65 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Personalized Gene Therapy Treatment Market Through 2025?
In recent times, there has been substantial growth in the market size of personalized gene therapy treatment. Predictions suggest that the market will expand from a worth of $6.93 billion in 2024 to $8.38 billion in 2025, experiencing a Compound Annual Growth Rate (CAGR) of 20.8%. Several factors contributed to this growth during the historic period such as heightened occurrences of genetic disorders, advancements made in gene editing technologies, increasing awareness around personalized medicine, as well as support in the form of government initiatives and funding. Additionally, an overall expansion in biotechnology research and infrastructure has also played a vital role.

What's the Projected Size of the Global Personalized Gene Therapy Treatment Market by 2029?
The market size for personalized gene therapy treatments is projected to undergo substantial expansion in the coming years, growing to a value of $17.65 billion by 2029 with a CAGR of 20.5%. Factors contributing to this expected growth during the forecast period include an increase in clinical trials for gene therapies, the incorporation of AI and predictive analytics in designing treatments, enhanced partnerships among pharmaceutical and biotech firms, improved efficiency and safety of delivery vectors, and a surge in the need for targeted and precision therapies. Major trends expected during this period comprise the integration of artificial intelligence and machine learning in therapy design, expansion of genomic sequencing capabilities, increasing partnerships between biotech and pharmaceutical companies, the inclusion of automation in gene therapy manufacturing systems, and utilization of blockchain technology for safeguarding genetic data.

View the full report here:
https://www.thebusinessresearchcompany.com/report/personalized-gene-therapy-treatment-global-market-report

Top Growth Drivers in the Personalized Gene Therapy Treatment Industry: What's Accelerating the Market?
The rising incidence of genetic diseases is predicted to drive the growth of the personalized gene therapy treatment market. Genetic diseases, which are conditions caused by DNA anomalies that interfere with normal bodily functions, are becoming more common due to an upward trend in parental age. Older reproductive cells carry a greater chance of transmitting mutations to offspring. Personalized gene therapy treats genetic diseases by accurately fixing the defective genes causing the disease and customizing the treatment according to the patient's genetic composition, improving effectiveness and minimizing potential side effects. For example, the Cystic Fibrosis Trust, a national charity based in the UK, reported in September 2023 that there were 11,148 registered cystic fibrosis (CF) patients in the UK in 2022. This marked an increase from 10,908 in 2021. Consequently, the escalating incidence of genetic diseases is fueling the expansion of the personalized gene therapy treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28293&type=smp

What Trends Will Shape the Personalized Gene Therapy Treatment Market Through 2029 and Beyond?
Major players in the personalized gene therapy treatment market are strategically partnering up to increase their technical abilities and deliver innovative treatments more effectively. Such strategic collaborations allow organizations to tap into each other's resources and expertise, fostering mutual growth and a competitive edge while sharing any risks and benefits involved. For instance, Aldevron, a U.S.-based firm known for its production of DNA, RNA, and protein, teamed up with Integrated DNA Technologies, a U.S.-based genomics solution provider, in May 2025. The partnership successfully led to the manufacturing of the world's first mRNA-based personalized CRISPR therapy. This groundbreaking treatment was developed to heal a child suffering from a rare and potentially fatal genetic disorder, urea cycle disorder (UCD). The creation of a custom guide RNA, an mRNA-encoded base editor, off-target safety services, and a clinically validated lipid nanoparticle delivery system, enabled the therapy to be developed and delivered in just six months. This achievement signifies a substantial advancement in personalized in vivo base-editing treatments.

What Are the Main Segments in the Personalized Gene Therapy Treatment Market?
The personalized gene therapy treatment market covered in this report is segmented as

1) By Therapy: Targeted Treatments, Pharmacogenomics
2) By Vector Type: Viral, Non-Viral
3) By Distribution Channel: Hospitals, Clinics, Home Administration, Other Distribution Channels
4) By Application: Oncology, Neurology, Hematological, Infectious Diseases, Ophthalmology, Other Applications

Subsegments:
1) By Targeted Treatments: Monoclonal Antibodies, Chimeric Antigen Receptor T-Cell Therapy (CAR-T), Small Interfering RNA (siRNA) Therapy, Antisense Oligonucleotides (ASO), Gene Editing Therapy
2) By Pharmacogenomics: Companion Diagnostics, Drug Metabolism Enzyme Testing, Genetic Biomarker Analysis, Single Nucleotide Polymorphism (SNP) Profiling, Adverse Drug Reaction (ADR) Prediction

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28293&type=smp

Which Top Companies are Driving Growth in the Personalized Gene Therapy Treatment Market?
Major companies operating in the personalized gene therapy treatment market are Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Kyowa Kirin Co. Ltd., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Rocket Pharmaceuticals Inc., REGENXBIO Inc., Intellia Therapeutics Inc., Beam Therapeutics Inc., Adaptimmune Therapeutics plc, Krystal Biotech Inc., Miltenyi Biomedicine GmbH, Bluebird Bio Inc., uniQure N.V., Mesoblast Limited, Astellas Gene Therapies Inc., Adverum Biotechnologies Inc., Autolus Therapeutics plc.

Which Regions Will Dominate the Personalized Gene Therapy Treatment Market Through 2029?
North America was the largest region in the personalized gene therapy treatment market in 2024. The regions covered in personalized gene therapy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28293

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.